SLNO•benzinga•
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Summary
Soleno's Vykat XR wins FDA approval as the first treatment for hyperphagia in Prader-Willi syndrome, with U.S. availability expected by April 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga